Antibiotic regimen | |
Empiric therapy | |
Early onset (<72 hours) | Ampicillin and gentamicin |
Late onset (≥72 hours) – Admitted from the community | Preferred regimen – Ampicillin and gentamicin Alternative – Ampicillin and an expanded-spectrum cephalosporin (eg, ceftazidime, cefepime, or cefotaxime [where available]) |
Late onset (≥72 hours) – Hospitalized since birth | Gentamicin and vancomycin* |
Special circumstances: | |
Suspected meningitis – Early onset or late onset, admitted from the community | Ampicillin, gentamicin, and an expanded-spectrum cephalosporin (eg, ceftazidime, cefepime, or cefotaxime [where available])¶ |
Suspected meningitis – Late onset, hospitalized since birth | Gentamicin, vancomycin, and an expanded-spectrum cephalosporin (eg, ceftazidime, cefepime, or cefotaxime [where available])¶ |
Suspected pneumonia | Ampicillin and gentamicin Alternatives:
|
Suspected infection of skin, umbilicus, soft tissues, joints, or bones (S. aureus is a likely pathogen) | Vancomycin and gentamicin, or Vancomycin, nafcillin, and gentamicin, or Vancomycin and an expanded-spectrum cephalosporin (eg, ceftazidime, cefepime, or cefotaxime [where available]) |
Suspected intravascular catheter-related infection | Vancomycin and gentamicin |
Suspected infection due to organisms found in the gastrointestinal tract (eg, anaerobic bacteria) | Ampicillin, gentamicin, and clindamycin Alternatives:
|
Pathogen-specific therapy | |
Group B Streptococcus | Penicillin G |
E. coli – Ampicillin-sensitive | Ampicillin |
E. coli – Ampicillin-resistant | Expanded-spectrum cephalosporin (eg, ceftazidime, cefepime, or cefotaxime [where available]) Alternative:
|
Multidrug-resistant gram-negative bacilli (including ESBL-producing organisms) | Meropenem |
L. monocytogenes | Ampicillin and gentamicin |
MSSA | Nafcillin or cefazolin |
MRSA | Vancomycin |
Coagulase-negative staphylococci | Vancomycin |
S. aureus: Staphylococcus aureus; E. coli: Escherichia coli; ESBL: extended-spectrum beta-lactamase; L. monocytogenes: Listeria monocytogenes; MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant S. aureus.
* A regimen of oxacillin or nafcillin plus gentamicin is reasonable if the neonate has a recent negative MRSA screening test.
¶ If there is concern for meningitis caused by a multidrug-resistant gram-negative organism, a carbapenem such as meropenem is the preferred agent for empiric therapy.